Project UpdateMay 13, 2026, 07:37 AM
MIRA Pharmaceuticals Publishes Positive Preclinical SKNY-1 Data
AI Summary
MIRA Pharmaceuticals, Inc. announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences detailing positive preclinical findings for SKNY-1, its investigational oral drug candidate for obesity and nicotine addiction. The study reported that SKNY-1 led to dose-dependent body weight reductions, including a 30% reduction in the higher-dose group, along with lipid normalization and attenuation of reward-associated behaviors in an MC4R-deficient zebrafish model. The company emphasized that these findings are based on preclinical research and SKNY-1 has not yet been approved by the FDA for any indication.
Key Highlights
- MIRA Pharmaceuticals announced publication of peer-reviewed manuscript on SKNY-1 in International Journal of Molecular Sciences.
- SKNY-1 is an investigational oral drug candidate for obesity and nicotine addiction.
- Preclinical data showed dose-dependent body weight reductions, up to approximately 30% in higher-dose zebrafish group.
- SKNY-1 normalized total cholesterol and LDL, increased HDL, and reduced hepatic triglyceride accumulation.
- It attenuated compulsive feeding and nicotine-seeking behaviors in multiple preclinical models.
- SKNY-1 demonstrated differential CB1 engagement, partial CB2 agonist activity, and selective MAO-B inhibition.
- Findings are based on preclinical research; SKNY-1 is not FDA approved for any indication.
Price Impact
More from MIRA